Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.
Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.
Stockwell's late son, Robert, was diagnosed with fibrolamellar cancer in 2013 at the age of 18. Even with published data and research on his cancer type, the family was still finding that it was difficult to get any true answers for his specific situation.
Now, Stockwell urges other patients not to just simply accept statistics and standards of care, and to advocate for themselves as an individual.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More